Results 91 to 100 of about 272,512 (195)

Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.

PLoS ONE, 2014
Neuroblastoma, a tumor of the peripheral sympathetic nervous system, is the most common and deadly extracranial tumor of childhood. The majority of high-risk neuroblastoma exhibit amplification of the MYCN proto-oncogene and increased neoangiogenesis ...
Raul Calero, Esther Morchon, John Inge Johnsen, Rosario Serrano   +3 more
doaj   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source

Proliferation and apoptosis subject to MYCN amplification in human neuroblastoma and their prognostic relevance

, 2011
Das Neuroblastom ist der häufigste solide extrakranielle Tumor im Kindesalter. Als entscheidendes molekulares Prognosekriterium hat sich die Amplifikation des N-Myc-Genes etabliert.
Dahms, Julian
core   +1 more source

Clinical, Histopathological, and Molecular Characterization of Pediatric MN1::ZNF341‐Associated Cancer

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT A lethal round‐cell malignancy with an MN1::ZNF341 fusion has recently been reported in three infants. Here, we describe four further tumors, three in newborns (including monozygotic twins), and one in an adolescent. Detailed clinical, radiological, and histopathological data differentiate these tumors from their main mimics, neuroblastoma and
Thomas R. W. Oliver, Dyanne Rampling, Barbara Walkowiak, Nathaniel D. Anderson, Manas Dave, Henry Lee‐Six, Sadie Baskind, Pooja Balasubramanian, Glenn Anderson, Conor Parks, Toochi Ogbonnah, Emilia R. Robertson, Simon Hannam, Rohan Verma, John C. Achermann, Liina Palm, Neil Sebire, Thomas Jacques, Tom Watson, Carryl Dryden, Karin Straathof, Mette Jorgensen, Olga Slater, Sam Behjati, Sarita Depani, J. Ciaran Hutchinson   +25 more
wiley   +1 more source

Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Background While the presence of metastases in neuroblastoma (NB) is a well‐established prognostic factor, the clinical significance of dissemination patterns and tumour burden and their impact on response and survival remains poorly understood.
Mariona Morell‐Daniel, Santiago Pérez‐Hoyos, Aroa Soriano, Ana Coma, Amalia Varo, Raquel Hladun, Gabriela Guillén, Soraya Mico, Marta Garrido, Lourdes Rubio, Alba Rubio‐San‐Simón, Ana Minguez, Ricardo López‐Almaraz, Laura Illade, Miguel F. Segura, Lucas Moreno   +15 more
wiley   +1 more source

Integrated Genomic and Proteomic Analysis Reveals T‐B Lymphocyte Signatures in the MYCN Driven “Immune Desert” of Specific Neuroblastoma Subtypes

CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
This study identifies a high‐risk neuroblastoma subtype defined by MYCN amplification and an “immune desert” tumor microenvironment. We uncover novel lymphocyte‐specific immunosuppressive networks, including T cell dysfunction and a MYC‐driven B cell hub, revealing potential therapeutic targets.
Jia‐Jian Hu, Wen‐Juan Kang, Jia‐Tong Hu, Ye‐Xiong Li, Feng‐Ju Song, Min Deng   +5 more
wiley   +1 more source

Rac GTPase regulation of 3D invasion in neuroblastomas lacking MYCN amplification

, 2017
Neuroblastomas are highly invasive tumors that occur in pediatric patients and treatment of invasive disease remains a challenge. The study of cells invading in 3-dimensional (3D) hydrogels has revealed morphologically distinct modes of invasion by which
Camilla B. Mitchell (2807428), Geraldine M. O'Neill (171987)   +1 more
core   +1 more source

Genetic variation associated with childhood and adult stature and risk of MYCN‐amplified neuroblastoma

Cancer Medicine, 2020
Background Neuroblastoma is the most common pediatric solid tumor. MYCN‐amplification is an important negative prognostic indicator and inherited genetic contributions to risk are incompletely understood.
Eleanor C. Semmes, Erica Shen, Jennifer L. Cohen, Chenan Zhang, Qingyi Wei, Jillian H. Hurst, Kyle M. Walsh   +6 more
doaj   +1 more source

TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β‐catenin/MYC axis

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Enzalutamide‐mediated AR suppression induces TMEM59L during prostate cancer progression. TMEM59L interacts with MUC1 and promotes its nuclear enrichment. Nuclear MUC1 activates β‐catenin/TCF4‐dependent MYC signalling, driving neuroendocrine differentiation, stemness and EMT.
Xiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu   +7 more
wiley   +1 more source

Supplementary Material for: Integrated Cytogenetic and High-Resolution Array CGH Analysis of Genomic Alterations Associated with MYCN Amplification

, 2017
Amplification of oncogenes and closely linked flanking genes is common in some types of cancer and can be associated with complex chromosome rearrangements and/or co-amplification of non-syntenic chromosomal regions. To better understand the etiology and
Pandita A. (4125685), Prasad M. (4125694), Squire J.A. (4122370), Graham C. (4125691), Paderova J. (4125676), Zielenska M. (4122364), Marrano P. (4125679), Bayani J. (4125682), Barrett M. (4125688)   +8 more
core   +1 more source